Our comprehensive pharmacogenomic assessment revealed a significant correlation between reduced expression of the NLRP1 gene in cancer patients and enhanced sensitivity to a spectrum of chemotherapeutic and targeted agents. This evidence concerns the gene NLRP1 and cancer.